Aspira Pathlab&Diagn Stock Price Analysis and Quick Research Report. Is Aspira Pathlab&Diagn an attractive stock to invest in?
Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.
Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements.
Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aspira Pathlab&Diagn.
-
PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aspira Pathlab&Diagn has a PE ratio of 24.9476903267343 which is high and comparatively overvalued.
-
Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aspira Pathlab&Diagn has ROA of -16.6745% which is a bad sign for future performance. (Higher values are always desirable.)
-
Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aspira Pathlab&Diagn has a Current ratio of 2.1028.
-
Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aspira Pathlab&Diagn has a ROE of -23.3445%. (Higher is better)
-
Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aspira Pathlab&Diagn has a Debt to Equity ratio of 0.1062 which means that the company has low proportion of debt in its capital.
-
Sales growth: Aspira Pathlab&Diagn has reported revenue growth of -8.6602% which is poor in relation to its growth and performance.
-
Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aspira Pathlab&Diagn for the current financial year is -8.99211656279109%.
-
Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aspira Pathlab&Diagn is Rs 0 and the yield is 0%.
-
Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aspira Pathlab&Diagn is Rs 2.4852. The higher the EPS, the better it is for investors.
One can find all the Financial Ratios of Aspira Pathlab&Diagn in Ticker for free. Also, one can get the intrinsic value of Aspira Pathlab&Diagn by using Valuation Calculators, which are available with a Finology ONE subscription.
Aspira Pathlab&Diagn FAQs
Q1. What is Aspira Pathlab&Diagn share price today?
Ans: The current share price of Aspira Pathlab&Diagn is Rs 62.
Q2. What is the market capitalisation of Aspira Pathlab&Diagn?
Ans: Aspira Pathlab&Diagn has a market capitalisation of Rs 63.8166 Cr., calculated based on its latest share price.
Q3. What are the P/E and P/B ratios of Aspira Pathlab&Diagn?
Ans: The PE ratio of Aspira Pathlab&Diagn is 24.9476903267343 and the P/B ratio of Aspira Pathlab&Diagn is 5.03046677863512, showing how the stock is valued against its earnings and book value.
Q4. What is the 52-week high and low of Aspira Pathlab&Diagn share?
Ans: The 52-week high share price of Aspira Pathlab&Diagn is Rs 106.78, and the 52-week low share price of Aspira Pathlab&Diagn is Rs 49.05.
Q5. Does Aspira Pathlab&Diagn pay dividends?
Ans: Currently, Aspira Pathlab&Diagn does not pay dividends. Dividend yield of Aspira Pathlab&Diagn is around 0%.
Q6. What are the face value and book value of Aspira Pathlab&Diagn shares?
Ans: The face value of Aspira Pathlab&Diagn shares is Rs 10, while the book value per share of Aspira Pathlab&Diagn is around Rs 12.3249. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.
Q7. What is the debt of Aspira Pathlab&Diagn?
Ans: Aspira Pathlab&Diagn has a total debt of Rs 1.0772 Cr., which affects investor sentiment and financial stability.
Q8. What are the ROE and ROCE of Aspira Pathlab&Diagn?
Ans: The ROE of Aspira Pathlab&Diagn is -23.3445% and ROCE of Aspira Pathlab&Diagn is -18.4858%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.
Q9. Is Aspira Pathlab&Diagn a good buy for the long term?
Ans: The Aspira Pathlab&Diagn long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.
Q10. Is Aspira Pathlab&Diagn undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aspira Pathlab&Diagn appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.
Q11. How to check Aspira Pathlab&Diagn’s financials?
Ans: You can review Aspira Pathlab&Diagn’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.